Beth Zelnick Kaufman serves as Executive Vice President, Chief Legal/Compliance Officer, and Corporate Secretary at CorMedix Inc., a biopharmaceutical company dedicated to developing innovative therapies for infectious and inflammatory diseases. In this pivotal role, she leads the company's legal strategy, regulatory compliance, risk management, and corporate governance efforts, ensuring alignment with FDA requirements, securities laws, and industry standards. Her oversight has been crucial in advancing CorMedix's pipeline, including the approval and commercialization of DefenCath, the company's novel antimicrobial catheter lock solution. With more than 25 years of experience in the pharmaceutical and biotechnology sectors, Beth brings a proven track record of navigating complex regulatory environments and executing high-stakes transactions. Prior to joining CorMedix in 2021, she was Senior Vice President and Chief Legal Officer at PTC Therapeutics, where she managed global legal operations, intellectual property portfolios, and strategic partnerships that supported rare disease drug development. Earlier in her career, she held senior roles at Alkermes, Inc., as Vice President and Deputy General Counsel, and at Bristol-Myers Squibb, contributing to major product launches, mergers, and acquisitions. Beth earned her J.D. from Fordham University School of Law and her B.A. from the University of Pennsylvania. Recognized for her strategic acumen and leadership in compliance programs, she has been instrumental in fostering a culture of integrity at CorMedix while driving business growth amid evolving healthcare regulations.